Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 9/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14907245 | 0.85 | NPC1 (0.47) | NPC1RAB9AKMT2AGRM5PDE10A | |
| SCHEMBL12680947 | 0.79 | NPC1 (0.55) | NPC1RAB9AKMT2AGRM5CNR2 | |
| SCHEMBL19104717 | 0.79 | CD4 (0.52) | NPC1RAB9AKMT2A | |
| SCHEMBL6210354 | 0.76 | NPC1 (0.52) | NPC1RAB9AKMT2AGRM5F10 | |
| SCHEMBL12680948 | 0.76 | NPC1 (0.63) | NPC1RAB9AKMT2AGRM5CNR2 | |
| SCHEMBL19296079 | 0.75 | GRM5 (0.48) | NPC1RAB9AKMT2AGRM5PDE10A | |
| SCHEMBL8051769 | 0.74 | GRM5 (0.51) | NPC1RAB9AKMT2AGRM5PDE10A | |
| SCHEMBL3536082 | 0.74 | NPC1 (0.50) | NPC1RAB9AKMT2AGRM5F10 | |
| SCHEMBL1202664 | 0.73 | NPC1 (0.52) | NPC1RAB9AKMT2AGRM5F10 | |
| SCHEMBL22993442 | 0.73 | PDE10A (0.44) | NPC1RAB9AKMT2AGRM5PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273772-B2 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-25 | — | — | US | disclosed |
| US-20100093689-A1 | HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| US-7645778-B2 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093689-A1 | HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS | P2RY1, P2RY11, P2RY2 | NPC1 1830/4885RAB9A 1636/4885KMT2A 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.